Vorasidenib is an orally available, selective brain-penetrant pan-IDH mutant inhibitor. Emerging areasNext generation targeted therapies. Tumor cells are generally observed to carry either an IDH1 or IDH2 mutation. The trial has completed enrollment. This trial has completed enrollment. PKR is the isoform of PK that is present in red blood cells, or RBCs. The initial four-year research term expired on May 17, 2020. Patent term adjustments or patent term extensions could result in later expiration dates. There are a number of marketed therapies available for treating patients with GDDs. These applications are submitted under Section 505(b)(1) of the FDCA. A ruling by the Supreme Court is expected sometime this year. In April 2014, the Clinical Trial (Regulation, (EU)) No 536/2014 was adopted. Strict deadlines have been established for the assessment of clinical trial applications. However, overall related timelines will be defined by the Clinical Trial Regulation. D.Decibel TherapeuticsMarc Tessier-Lavigne, Ph. As of December 31, 2020, 57% of our workforce were women. We expect to incur losses in the future and may never achieve or maintain profitability. We depend heavily on the success of our clinical product candidates. We are also pursuing product candidates to treat patients with GDDs. A broad range of legislative measures also have been introduced at the federal level. Each of these lawsuits was settled in 2012. Unpatented proprietary technical information and know-how can be difficult to protect. We cannot predict how federal agencies will respond to such Executive Orders. We do not maintain "key person" insurance for any of our executives or other employees.
